Market Overview - The Dow Jones Industrial Average, S&P 500, and Nasdaq Composite have all experienced double-digit percentage declines, with the Nasdaq entering a bear market with a loss exceeding 20% from its all-time high [2][3] - The recent declines have been characterized by their rapid velocity, with significant single-session point and percentage declines recorded [3] Tariff Policy Impact - President Trump's tariff policy has been a pivotal factor in the recent market downturn, with a 10% global tariff and higher reciprocal tariffs on countries with negative trade balances with the U.S. announced [4][5] - The potential for tariffs to increase domestic goods prices and reignite inflation is a concern, as input tariffs could make U.S. products less competitive [6] - Tariffs may also harm trade relations and create uncertainty in the market, as the president frequently changes which products or countries are affected [7] Investment Opportunities - The current market volatility presents an opportunity for long-term investors to acquire stocks at discounted prices [8] - Johnson & Johnson offers a 3.31% yield and has increased its annual payout for 63 consecutive years, indicating a strong dividend history [9] - Johnson & Johnson holds a AAA credit rating, reflecting confidence in its ability to service and repay debts [10][11] - The company's operating model is expected to remain stable despite tariff concerns, as demand for healthcare products is consistent [12] - Johnson & Johnson's focus on novel-drug development and its historically inexpensive stock valuation (14 times forward-year earnings) make it an attractive investment [14][15] Sirius XM Holdings - Sirius XM Holdings provides a 5.36% yield and operates as a legal monopoly in satellite radio, giving it pricing power over competitors [16][17] - The company generates 76% of its net sales from self-pay subscriptions, making it less vulnerable to economic downturns compared to traditional radio operators reliant on advertising [19] - Sirius XM's stock is valued at 6.6 times forward-year earnings, representing a 55% discount to its average forward P/E multiple from 2019 to 2024 [20]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 30, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) ...

TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Phase 2b SunRISe-1 study (Cohort 2)Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study show potential of TAR-200 monotherapy in patients with papillary-only, high-risk non-muscle invasive bladder cancerRARITAN, N.J., April 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that new data from its leading oncology pipeline will be presented at the American Urological Association ...

Group 1: U.S. Credit Ratings - In 2011, S&P Global Ratings downgraded the U.S. long-term credit outlook from AAA to AA+ due to budgetary issues, with Fitch downgrading U.S. credit again in 2023 and Moody's considering a similar move [1] - The 2024 fiscal deficit has ballooned to over $1.8 trillion, exacerbating debt and fiscal issues [1] Group 2: Microsoft - Microsoft holds AAA and Aaa ratings from S&P and Moody's, respectively, and has seen its stock fall about 12% this year, outperforming peers in the "Magnificent Seven" [4][6] - The company has a diverse business model across various tech sectors, including cloud, video games, and AI, and was an early investor in OpenAI [4] - Microsoft has a strong balance sheet with over $71.5 billion in cash and equivalents, approximately $40 billion in long-term debt, and equity exceeding $302 billion, resulting in a low debt-to-equity ratio [6] Group 3: Johnson & Johnson - Johnson & Johnson is the only other U.S. company with top credit ratings and recently announced an acquisition of Intra-Cellular Therapies for $14.6 billion, which may impact its credit rating due to increased debt [7] - The stock has performed well, up nearly 9% this year, and the company raised its full-year revenue outlook to $91.4 billion from $89.4 billion [8] - Johnson & Johnson's CFO indicated that the guidance includes a $400 million impact from tariffs, which could affect stock performance if trade tensions with China persist [9] - At the end of 2024, Johnson & Johnson had over $24 billion in cash, about $30.6 billion in long-term debt, and over $71 billion in total equity, maintaining a strong balance sheet despite the recent acquisition [10]

Earlier this week, J&J (JNJ) began the first-quarter earnings season for the drug and biotech sector with better-than-expected results.J&J’s first-quarter adjusted earnings were $2.77 per share, which rose 2.2% from the year-ago period. Sales of $21.89 billion rose 2.4% from the year-ago quarter. Innovative Medicines segment sales rose 2.3% year over year to $13.87 billion. MedTech segment sales came in at $8.02 billion, up 2.5% from the year-ago period.The company raised its sales expectations for 2025 by ...

Johnson & Johnson (JNJ 0.22%) continues to treat its investors like royalty. The healthcare behemoth recently gave them another raise, increasing its dividend payment by 4.8%. That extended its dividend growth streak to an impressive 63 years in a row, keeping it in the elite group of Dividend Kings, companies with 50 or more years of annual dividend increases. That payout boost pushes the company's forward dividend yield up to 3.4%, more than double the S&P 500's dividend yield of 1.4%. Johnson & Johnson's ...

Johnson & Johnson (JNJ) reported stronger-than-expected first-quarter 2025 results. The world's biggest healthcare products maker continued with its long streak of earnings beat and also exceeded revenue estimates. It raised its revenue guidance for this year amid tariff chaos and boosted its quarterly dividends.Given the resilience of the drugmaker amid the potential tariff shifts under the Trump administration, investors should tap the company’s growth prospects through ETFs with the largest allocation to ...

Core Viewpoint - Johnson & Johnson reported solid earnings, beating expectations on both revenue and earnings, while providing better-than-expected guidance despite acknowledging a potential $400 million tariff impact on its medical device business [2][3][4]. Financial Performance - The company’s stock price is currently at $153.66, with a P/E ratio of 23.11 and a dividend yield of 3.23% [2]. - J&J's MedTech division experienced a year-over-year revenue growth of approximately 4.3%, with forecasts of 5-7% annual growth [10]. Tariff Impact - The anticipated $400 million tariff hit is viewed as a worst-case scenario, with ongoing uncertainty regarding future policy moves [4][5]. - The company is currently affected by existing steel and aluminum tariffs, with potential additional tariffs on pharmaceuticals once exemptions are lifted [5]. Innovative Medicine Developments - Johnson & Johnson is a leader in precision medicine, with significant advancements in gene therapy, particularly with the approval of the Rybrevant drug for non-small-cell lung cancer [7][8]. - The long-term potential of Rybrevant is highlighted, especially following the expiration of the patent for its blockbuster drug Stelara [8]. Litigation Issues - Ongoing litigation related to talc products remains a concern, with the company’s attempt to separate these liabilities into a different entity being rejected by courts [11]. - This litigation adds uncertainty for shareholders, as the company must continue to navigate these legal challenges [11]. Dividend and Investment Outlook - Johnson & Johnson has a strong dividend history, recently increasing its dividend for the 63rd consecutive year, with an annual dividend of $4.96 [12][13]. - Analysts suggest a potential upside of approximately 11% for the stock, making it a candidate for a buy-and-hold strategy, especially given its current trading position within its 52-week range [14].

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Slide footer goes here if required 1 1st Quarter 2025 Earnings Call April 15, 2025 Cautionary note on Forward-looking statements This presentation contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectatio ...